Target intelligence / Profile preview

Deleted in esophageal cancer 1 (DELEC1)

Target
DELEC1
Molecular classification
lncRNA (long non-coding RNA)
01

Overview

Deleted in esophageal cancer 1 is an RNA gene located on chromosome 9q33.1, commonly deleted in esophageal squamous cell carcinomas, with reduced or absent expression in these tumors. It is considered a candidate tumor suppressor gene due to its frequent loss or reduction in expression in multiple cancers. DELEC1 is categorized as a long non-coding RNA (lncRNA) gene and is not confirmed to encode a protein. Current research has not delineated a specific biological function or molecular mechanism, and no established drugs, clinical biomarkers, or safety concerns are documented in relation to this gene. Some literature and database entries inadvertently conflate DELEC1 with DLEC1, which is a protein-coding tumor suppressor involved in cell proliferation and may have different functionalities. If your context is strictly about the DELEC1 gene on chromosome 9 annotated as a non-coding RNA, it is best considered a putative tumor suppressor and not a validated drug target or receptor.

Other names
DELEC1CTS9DEC1Candidate tumor suppressor 9Candidate tumor suppressor CTS9
02

Biological functions

Putative tumor suppressor activityNegative regulation of cell proliferation (from gene location correlation and expression studies)
03

Disease associations

Cancer (specifically esophageal squamous cell carcinoma; associations also reported for lung, breast, pancreatic, liver, and oral cavity cancers based mainly on gene expression studies)

Beyond the preview

Go deeper on Deleted in esophageal cancer 1 (DELEC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deleted in esophageal cancer 1 (DELEC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call